Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 17-Apr-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...
GENEVA, SWITZERLAND / ACCESSWIRE / November 7, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, ...
Relief Therapeutics (OTCQB:RLFTF)(OTCQB:RLFTD) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil). The company said the data showed high ...
GENEVA, SWITZERLAND / ACCESSWIRE / April 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to ...
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil) 03-Aug-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The ...
RLF-100 ® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, which was first discovered in 1970. Although initially identified in the intestinal ...
GENEVA, SWITZERLAND / ACCESSWIRE / August 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic ...
RLF-100 ® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, which was first discovered in 1970. Although initially identified in the intestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback